Shuttle Pharmaceuticals Holdings, Inc.
SHPHShuttle Pharmaceuticals Holdings, Inc. in brief
Shuttle Pharmaceuticals Holdings, Inc. is a listed company in the Biotechnology industry, based in Gaithersburg, Maryland, USA. Its market value was $3 M on 1 August 2026, which makes it the 27,383rd largest listed company in the world and the 4,464th largest in the USA on this site. Ryan Trasolini is its chief executive. Its shares trade under the symbol SHPH (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Shuttle Pharmaceuticals Holdings, Inc.
On November 21, 2025, we acquired substantially all of the assets and liabilities of Molecule.ai, a pharmaceutical software company building an artificial intelligence driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development. The platform is engineered to accelerate the iteration cycles that characterize modern drug discovery while preserving scientific reproducibility, traceability and operational reliability. Molecule.ai adapts state of the art AI algorithms to create a practical, domain-specific AI infrastructure layer for molecular research and development. We will seek to leverage Molecule.ai’s molecular modeling and predictive analytics platform to significantly augment our drug discovery and development business purpose. In tandem with the Molecule.ai asset acquisition, on November 20, 2025, we committed to a plan to wind-down our clinical trials of Ropidoxuridine, our lead product candidate.
From the company's annual report filed with the US SEC: read the report
Shuttle Pharmaceuticals Holdings, Inc. timeline
- 2019
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2022
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 31 August 2022; shares registered for exchange trading on 29 August 2022.
Events of Shuttle Pharmaceuticals Holdings, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,112 (Dec 2022) · #5,363 (Jul 2023) · #4,534 (Jan 2024) · #2,469 (Mar 2026) · #4,158 (Aug 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.3×
- Free cash flow yield
- -186.7%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -520.9%
- Liabilities / assets
- 78.4%
- Net debt
- $-0M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-12M | $-12M | — |
| Dec 2024 | — | — | $-8M | $-9M | — |
| Dec 2023 | — | — | $-6M | $-7M | — |
| Dec 2022 | — | — | $-2M | $-5M | — |
| Dec 2021 | — | — | $-2M | $-1M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-9M | — | — | $-7.16 | — |
| Dec 2024 | $-7M | — | — | $-82.60 | — |
| Dec 2023 | $-6M | $0M | $-6M | $-3.53 | — |
| Dec 2022 | $-3M | — | — | $-5.04 | — |
| Dec 2021 | $-0M | — | — | — | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 6, 20268-KCurrent reportAuditor change
- Oct 22, 20268-KCurrent reportAuditor change
- Sep 24, 202610-QQuarterly report · period to Jun 2026
- Sep 24, 20268-K/ACurrent report (amended)
- Sep 16, 20268-KCurrent reportUnregistered share sale
- Sep 11, 20268-KCurrent reportShareholder vote
- Sep 2, 20268-KCurrent reportOther events
- Sep 1, 20268-KCurrent reportMaterial agreement
- Aug 28, 20268-KCurrent reportListing notice · Regulation FD disclosure
- Aug 17, 20268-K/ACurrent report (amended)Acquisition or disposal completed
- Aug 13, 2026DEF 14AProxy statement
- Jul 1, 20268-KCurrent reportRegulation FD disclosure · Other events
Official filings of Shuttle Pharmaceuticals Holdings, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-12 M
- Net income
- $-12 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $10 M
- Total liabilities
- $8 M
- Total equity
- $2 M
As of December-2025
Top 5 institutional investors in Shuttle Pharmaceuticals Holdings, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 19,445 | New | 0.41% | $0 M | Nov 12, 2026 |
| 2 | Geode Capital Management, LLC | 14,715 | New | 0.31% | $0 M | Nov 6, 2026 |
| 3 | UBS Group AG | 5,730 | New | 0.12% | $0 M | Nov 10, 2026 |
| 4 | Tower Research Capital LLC (TRC) | 1,762 | +1,373 (+352.96%) | 0.04% | $0 M | Nov 16, 2026 |
| 5 | Kelleher Financial Advisors | 120 | 0 (0.00%) | 0.00% | $0 M | Oct 30, 2026 |
Insider trading at Shuttle Pharmaceuticals Holdings, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | HRT Financial LP10% owner | Sell | -82,116 | $4.480 | $368 K | 0 | Form 4 |
| filed | HRT Financial LP10% owner | Sell | -1,033 | $4.670 | $5 K | 60,238 | Form 4 |
| filed | HRT Financial LP10% owner | Buy | +731 | $3.110 | $2 K | 61,271 | Form 4 |
| filed | HRT Financial LP10% owner | Buy | +8,266 | $3.380 | $28 K | 60,540 | Form 4 |
| filed | HRT Financial LP10% owner | Sell | -18,531 | $3.520 | $65 K | 52,274 | Form 4 |
| filed | HRT Financial LP10% owner | Sell | -10,580 | $3.330 | $35 K | 70,805 | Form 4 |
| filed | HRT Financial LP10% owner | Sell | -9,022 | $3.510 | $32 K | 81,385 | Form 4 |
| filed | HRT Financial LP10% owner | Buy | +7,851 | $3.540 | $28 K | 90,407 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Shuttle Pharmaceuticals Holdings, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-06-10 23:50 UTC, code T1, resumed 13:00 UTC
- 2025-10-10 15:43 UTC, code LUDP, resumed 15:48 UTC
- 2025-10-10 15:03 UTC, code LUDP, resumed 15:13 UTC
- 2025-10-10 14:56 UTC, code LUDP, resumed 15:01 UTC
- 2025-07-15 19:57 UTC, code LUDP, resumed 20:00 UTC
Fails to deliver
- : 2,944 shares at $5.24
- : 358 shares at $5.21
- : 2,322 shares at $5.05
- : 3,929 shares at $4.86
- : 19 shares at $4.91
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Shuttle Pharmaceuticals Holdings, Inc. scorecard#
Passes 0 of the 6 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-7.16 vs -82.60Diluted EPS -7.16 in fiscal 2025 against -82.60 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$12 MNet income -$12 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-791.9%-791.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 2
- ✗Short-term assets cover short-term liabilities0.1×Current ratio 0.06 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Shuttle Pharmaceuticals Holdings, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Research and development | 4,055+12.0%— | 3,619+2.9%— | 3,517+236%— | 1,047r1,489+2.5%— | 1,022—— | |
| General and administrative | 5,673+307%— | 1,393+33.0%— | 1,047+121%— | 474r199+1198%— | 37—— | |
| Operating expenses | 11,917+54.8%— | 7,696+30.6%— | 5,892+151%— | 2,344r2,554+34.5%— | 1,743—— | |
| Total costs and expenses | 2,400+14.3%— | 2,100+2000%— | 100—— | — | — | |
| Operating income | −11,917—— | −7,696—— | −5,892—— | −2,344r−2,554—— | −1,743—— | |
| Interest and finance income | 1.1−97.1%— | 38−51.8%— | 79—— | — | — | |
| Interest expense and finance costs | — | — | 2,123+131%— | 918+23797%— | 3.8—— | |
| Net interest income | — | 1000.0%— | 100r53—— | — | — | |
| Other non-operating income (expense) | 195—— | −1,449—— | −700—— | −2,652r−474−549%— | 591—— | |
| Income before tax | — | — | −6,593—— | −4,996r−3,028—— | −1,152—— | |
| Net income including minority interests | — | −9,540—— | — | 1,688—— | — | |
| Net income attributable to shareholders | −11,722—— | −9,145—— | −6,593—— | −4,996r−3,028—— | −1,152—— | |
| Earnings per share, basic | -7.16—— | -79.65r-3.19—— | -3.53r-0.44—— | -5.04r-0.29—— | -0.12—— | |
| Earnings per share, diluted | -7.16—— | -82.60r-3.30—— | -3.53r-0.44—— | -5.04r-0.29—— | — | |
| Shares, weighted average (basic) | 1.6+1327%— | 0.1r2.9−93.8%— | 1.9r15+39.5%— | 1.3r10−85.6%— | 9.3—— | |
| Shares, weighted average (diluted) | 1.6+1318%— | 0.1r2.9−93.8%— | 1.9r15+39.5%— | 1.3r10—— | — | |
| Balance sheet | ||||||
| Cash and cash equivalents | 334−82.6%3.2% | 1,920−25.5%76.6% | 2,576−69.4%43.3% | 8,417+1568%97.3% | 505—77.5% | |
| Short-term investments | — | — | 2,887—48.5% | — | — | |
| Other current assets | 169−41.9%1.6% | 291—11.6% | — | — | 4.9—0.7% | |
| Current assets | 503−77.3%4.8% | 2,211−60.5%88.2% | 5,593−34.8%94.0% | 8,578+1583%99.1% | 510—78.2% | |
| Property, plant and equipment | 17−10.6%0.2% | 19−22.0%0.8% | 25+97.2%0.4% | 13−32.2%0.1% | 19—2.8% | |
| Right-of-use (leased) assets | 102−62.9%1.0% | 276−17.3%11.0% | 334+495%5.6% | 56−52.0%0.6% | 117—18.0% | |
| Other intangible assets | 9,841—93.9% | — | — | — | — | |
| Total assets | 10,476+318%100% | 2,506−57.9%100% | 5,952−31.2%100% | 8,654+1228%100% | 652—100% | |
| Accounts payable | 1,454+144%13.9% | 597—23.8% | — | — | — | |
| Customer deposits | — | — | 6.5—0.1% | — | — | |
| Current liabilities | 7,967+419%76.0% | 1,534+47.2%61.2% | 1,042+6.8%17.5% | 976−56.0%11.3% | 2,217—340% | |
| Lease liabilities (non-current) | 155−34.9%1.5% | 238−21.7%9.5% | 304—5.1% | — | 62—9.6% | |
| Total liabilities | 8,222+357%78.5% | 1,797−5.2%71.7% | 1,896+94.3%31.9% | 976−57.2%11.3% | 2,280—350% | |
| Retained earnings | −46,300—−442% | −34,578—−1380% | −25,433r−15,488—−427% | −18,841r−8,895—−218% | −13,845r−5,795—−2125% | |
| Shareholders' equity | 2,254+218%21.5% | 709−82.5%28.3% | 4,056r4,056−47.2%68.1% | 7,678—88.7% | −1,764r−1,628—−271% | |
| Total liabilities and equity | 10,476+318%100% | 2,506−57.9%100% | 5,952−31.2%100% | 8,654+1228%100% | 652—100% | |
| Shares outstanding | 0.2r2.0+24.1%— | 0.2r4.1−91.9%— | 2.0r16+18.1%— | 1.7r14−81.7%— | 9.3—— | |
| Cash-flow statement | ||||||
| Depreciation and amortization | 290+5210%— | 5.5—— | — | — | — | |
| Share-based compensation | 933+259%— | 260+42.7%— | 182−23.4%— | 238r404−73.9%— | 910—— | |
| Cash from operating activities | −9,482—— | −7,327—— | −5,581—— | −2,666r−2,710—— | −300—— | |
| Capital expenditure | — | — | −19—— | — | — | |
| Cash from investing activities | −3,057−205%— | 2,916—— | −2,830—— | — | — | |
| Debt repaid | — | −60—— | — | — | — | |
| Shares issued | — | 3,993—— | — | 10,022—— | — | |
| Cash from financing activities | 10,952+192%— | 3,755+46.1%— | 2,570−75.7%— | 10,579r10,623+1438%— | 688—— | |
| Change in cash | −1,586—— | −656—— | −5,841−174%— | 7,912+1941%— | 388—— | |
| Report | 10-K | 10-K | 10-K | 10-K/A | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 | Q2 FY2023to Jun 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 1,778−64.3%— | 56−94.6%— | 267−83.0%— | 512*−48.1%— | 943−32.6%— | 1,026+58.8%— | 1,574—— | 986*+38.8%— | 1,401+34.0%— | 646−23.1%— | 710r433*—— | 1,045r1,140—— | 840r933—— | |
| General and administrative | 5,875+58.7%— | 1,985−15.4%— | 1,161+94.4%— | 1,844*+330%— | 886+169%— | 2,346+657%— | 597—— | 429*+35.5%— | 329+23.9%— | 310+48.1%— | 317r595*—— | 266r170—— | 209r116—— | |
| Operating expenses | 11,222−4.0%— | 3,950+1.0%— | 2,217−24.9%— | 2,788*+56.9%— | 2,267−25.7%— | 3,910+164%— | 2,951—— | 1,777*+38.5%— | 3,052+90.8%— | 1,483+1.2%— | 1,283*—— | 1,599—— | 1,466—— | |
| Operating income | −11,222—— | −3,950—— | −2,217—— | −2,788*—— | −2,267—— | −3,910—— | −2,951—— | −1,777*—— | −3,052—— | −1,483—— | −1,283*—— | −1,599—— | −1,466—— | |
| Interest and finance income | 1.3—— | 0.1+11.1%— | 0.2—— | 0.5*+17333%— | 0.5−80.7%— | 0.1−99.4%— | — | 0.0*−100.0%— | 2.5−87.8%— | 14−26.5%— | 22*—— | 21—— | 19—— | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | — | 387−29.6%— | 573*—— | 623r538—— | 549—— | |
| Net interest income | — | — | — | — | — | — | — | — | — | — | 43r−3.9*—— | 21*—— | 19r23*—— | |
| Other non-operating income (expense) | 961—— | 804+294%— | 64—— | 173*−3.0%— | −80—— | 204—— | −102—— | 179*—— | −733—— | −549—— | −358*—— | −194—— | −719—— | |
| Income before tax | — | — | — | — | — | — | — | — | — | — | −1,641*—— | −1,775—— | — | |
| Net income including minority interests | — | — | — | — | −2,300*—— | −3,800*—— | −3,000—— | — | — | — | — | 1,311*—— | 1,049*—— | |
| Net income attributable to shareholders | −10,260—— | −3,146—— | −2,152—— | −2,615*—— | −2,347—— | −3,706—— | −3,053—— | −1,598*—— | −3,784—— | −2,031—— | −1,641*—— | −1,793—— | −2,184—— | |
| Earnings per share, basic | — | -3.10—— | -0.43—— | — | -1.05—— | -32.91r-3.29—— | -7.60r-0.30—— | — | -39.83r-1.59—— | -24.12r-0.96—— | — | -0.91r-0.11—— | -1.23r-0.15—— | |
| Earnings per share, diluted | — | -3.10—— | -0.43—— | — | -1.05—— | -32.91r-3.29—— | -7.60r-0.30—— | — | -39.83r-1.59—— | -24.12r-0.96—— | — | -0.91r-0.11—— | -1.23r-0.15—— | |
| Shares, weighted average (basic) | 1.0+801%— | 1.0+801%— | 5.0+1152%— | — | 2.2+2251%— | 0.1r1.1+33.7%— | 0.4r10—— | — | 0.1r2.4−95.2%— | 0.1r2.1−95.3%— | — | 2.0r16—— | 1.8r14—— | |
| Shares, weighted average (diluted) | 1.0+801%— | 1.0+801%— | 5.0+1152%— | — | 2.2+2251%— | 0.1r1.1+33.7%— | 0.4r10—— | — | 0.1r2.4−95.2%— | 0.1r2.1−95.3%— | — | 2.0—— | 1.8r14—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 90—0.4% | 90−98.1%0.4% | 1,090−75.8%9.2% | 334−82.6%3.2% | 2,095+1237%59.1% | 4,818+593%87.5% | 4,513—85.0% | 1,920−25.5%76.6% | 157−96.0%23.3% | 696−87.2%24.7% | 2,576—43.3% | 3,886—52.7% | 5,447—61.6% | |
| Short-term investments | — | — | — | — | — | — | — | — | — | 1,643−43.4%58.4% | 2,887—48.5% | 2,921—39.6% | 2,904—32.9% | |
| Other current assets | 306—1.3% | 306—1.3% | 1,373—11.6% | 169−41.9%1.6% | 1,171—33.1% | — | — | 291—11.6% | — | — | — | 6.5—0.1% | 6.5—0.1% | |
| Current assets | 396—1.7% | 396−92.4%1.7% | 2,463−50.3%20.9% | 503−77.3%4.8% | 3,266+804%92.2% | 5,192+109%94.3% | 4,959—93.4% | 2,211−60.5%88.2% | 361−94.8%53.6% | 2,485−70.6%88.4% | 5,593—94.0% | 6,996—94.8% | 8,443—95.5% | |
| Property, plant and equipment | 15—0.1% | 15−21.4%0.1% | 16−11.1%0.1% | 17−10.6%0.2% | 18−13.4%0.5% | 19−11.9%0.4% | 18—0.3% | 19−22.0%0.8% | 21−21.1%3.1% | 22+128%0.8% | 25—0.4% | 27—0.4% | 9.6—0.1% | |
| Right-of-use (leased) assets | 67—0.3% | 67−72.4%0.3% | 85−67.3%0.7% | 102−62.9%1.0% | 228−21.5%6.4% | 245−20.0%4.4% | 261—4.9% | 276−17.3%11.0% | 291−17.6%43.2% | 306−20.4%10.9% | 334—5.6% | 353—4.8% | 384—4.3% | |
| Other intangible assets | 8,649—37.9% | 8,649—37.9% | 9,245—78.3% | 9,841—93.9% | — | — | — | — | — | — | — | — | — | |
| Total assets | 22,811—100% | 22,811+314%100% | 11,809+122%100% | 10,476+318%100% | 3,543+426%100% | 5,504+95.7%100% | 5,310—100% | 2,506−57.9%100% | 674−90.9%100% | 2,813−68.2%100% | 5,952—100% | 7,376—100% | 8,837—100% | |
| Accounts payable | 2,787—12.2% | 2,787+137%12.2% | 1,790+99.5%15.2% | 1,454+144%13.9% | 1,473—41.6% | 1,174—21.3% | 897—16.9% | 597—23.8% | — | — | — | — | — | |
| Customer deposits | — | — | — | — | — | — | — | — | — | — | 6.5—0.1% | 6.5—0.1% | 6.5—0.1% | |
| Current liabilities | 3,481—15.3% | 3,481+106%15.3% | 8,306+366%70.3% | 7,967+419%76.0% | 1,965+18.4%55.5% | 1,693+22.3%30.8% | 1,782—33.6% | 1,534+47.2%61.2% | 1,659+105%246% | 1,385+180%49.2% | 1,042—17.5% | 810—11.0% | 494—5.6% | |
| Lease liabilities (non-current) | 112—0.5% | 112−42.4%0.5% | 134−39.1%1.1% | 155−34.9%1.5% | 175−31.4%4.9% | 195−26.9%3.5% | 220—4.1% | 238−21.7%9.5% | 256−17.1%37.9% | 267−19.0%9.5% | 304—5.1% | 308—4.2% | 330—3.7% | |
| Total liabilities | 3,629—15.9% | 3,629+91.1%15.9% | 8,463+318%71.7% | 8,222+357%78.5% | 2,149+8.0%60.6% | 1,899−5.6%34.5% | 2,025—38.1% | 1,797−5.2%71.7% | 1,989+12.6%295% | 2,012+5.8%71.5% | 1,896—31.9% | 1,766—23.9% | 1,901—21.5% | |
| Retained earnings | −51,598—−226% | −51,598—−226% | −48,452—−410% | −46,300—−442% | −43,685—−1233% | −41,338—−751% | −37,631—−709% | −34,578—−1380% | −32,980—−4896% | −29,196—−1038% | −25,433r−15,488—−427% | −23,793r−13,847—−323% | −12,054—−136% | |
| Shareholders' equity | 19,182—84.1% | 19,182+432%84.1% | 3,346r3,346+1.9%28.3% | 2,254+218%21.5% | 1,394—39.4% | 3,606+350%65.5% | 3,285—61.9% | 709−82.5%28.3% | −1,315−123%−195% | 801r801−88.4%28.5% | 4,056r4,056—68.1% | 5,610—76.1% | 6,936r6,936—78.5% | |
| Total liabilities and equity | 22,811—100% | 22,811+314%100% | 11,809+122%100% | 10,476+318%100% | 3,543+426%100% | 5,504+95.7%100% | 5,310—100% | 2,506−57.9%100% | 674−90.9%100% | 2,813−68.2%100% | 5,952—100% | 7,376—100% | 8,837—100% | |
| Shares outstanding | 1.0—— | 1.0−6.5%— | 5.6−13.0%— | 0.2r2.0+24.1%— | 1.2−58.1%— | 1.1−49.2%— | 6.4—— | 0.2r4.1−91.9%— | 2.9−81.6%— | 2.1−86.4%— | 2.0r16—— | 16—— | 15—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | 633*—— | 633+62731%— | — | — | — | 1.0—— | — | — | — | — | — | — | |
| Share-based compensation | 377−43.0%— | −7.5−116%— | 35−93.5%— | 215*+574%— | 134+197%— | 47−34.2%— | 537—— | 32*−63.2%— | 45+20.5%— | 71+43.7%— | 87*—— | 38*—— | 50*—— | |
| Cash from operating activities | −6,585—— | −568*—— | −2,417—— | −973*—— | −2,627*—— | −3,355*—— | −2,527—— | −2,690*—— | −1,999*—— | — | −1,062*—— | −1,535*—— | −1,646*—— | |
| Capital expenditure | — | — | — | — | — | — | — | — | — | — | 0*—— | — | — | |
| Cash from investing activities | — | −5,433*—— | −36—— | — | — | — | — | 0*−100%— | 1,656*—— | — | 87*—— | −26*—— | 63*—— | |
| Shares issued | — | 0*−100%— | 3,225−40.4%— | — | −4,080r0*—— | 4,080r0*—— | 5,410—— | — | — | — | — | — | — | |
| Cash from financing activities | 10,383−20.4%— | 5,001*+36.6%— | 3,209−37.3%— | 2,269*−49.1%— | −96*—— | 3,660*—— | 5,119—— | 4,454*—— | −197*—— | — | −334*—— | 0*—— | −139*—— | |
| Change in cash | −4,727−215%— | −1,000*−428%— | 756−70.8%— | −1,761*−200%— | −2,723*—— | 305*—— | 2,592—— | 1,763*—— | −539*—— | — | −1,310*—— | −1,561*—— | −1,722*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Shuttle Pharmaceuticals Holdings, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 2 · Auditor changed 2 · Restructuring 1 · Acquisition or sale completed 3 · Directors and officers 8 · Material agreement 10 · Agreement ended 2 · Unregistered share sale 6 · Shareholder rights changed 2 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 1
| Filed | What happened | Filing |
|---|---|---|
| Auditor changed | 8-K | |
| Auditor changed | 8-K | |
| Unregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Acquisition or sale completed | 8-K/A | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Acquisition or sale completedMaterial agreementUnregistered share sale | 8-K | |
| RestructuringMaterial agreementAgreement ended | 8-K | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2026 | $10 M | Private placement after listing | $2 to $10 million | 47 | equity, options | SEC |
| Nov 2025 | $3 M | Private placement after listing | $2 to $10 million | 1 | options | SEC |
| Jun 2025 | $4 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Shuttle Pharmaceuticals Holdings, Inc. compares in Biotechnology
- Market cap$3 M · higher than 2% of 726
- Price / book1.3× · lower than 71% of 534
- FCF yield-186.7% · higher than 2% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Shuttle Pharmaceuticals Holdings, Inc.🇺🇸 | $3 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Shuttle Pharmaceuticals Holdings, Inc.? Verify and update this profile — free
Show Shuttle Pharmaceuticals Holdings, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.